Sato T Shawn,  Sato Yutaka

Final Pr. ID: Poster #: EDU-084

The 2016 World Health Organization Classification of Tumors of the Central Nervous System has now incorporated molecular and genetic parameters in addition to histology to define many tumor entities. Significant restructuring has occurred for pediatric CNS tumors. For example, medulloblastomas are classified into four genetic subtypes. Other embryonal tumors such as embryonal tumor with multilayered rosettes (ETMR) and atypical teratoid/rhabdoid tumor (ATRT) are further defined by their molecular features. Also new entities have been added defined by both histology and molecular signatures including H3 K27M-mutant diffuse midline glioma, RELA fusion-positive ependymoma and diffuse leptomeningeal glioneuronal tumor (DLGNT).
These more homogeneous and narrowly defined entities are expected to facilitate better classification, prognostication and patient stratification for precision therapy. This also improves the design of clinical trials and experimental models.
In this presentation, we will review the new WHO classification scheme and review the imaging and as well as molecular/genetic features of pediatric CNS tumors.
Radiologists must keep up to date with updates to the WHO classification scheme to be able to better communicate with clinicians ensure optimal patient care and relevant research collaboration.
Read More

Authors:  Sato T Shawn , Sato Yutaka

Keywords:  WHO, Brain tumors

Willard Scott,  Barnes Craig,  Augustyn Robyn,  Thorkelson Marrit,  Chatfield Paige,  Hu Harry,  Towbin Richard,  Bardo Dianna,  Pfeifer Cory,  Dance Logan,  Bailey Smita,  Southard Richard,  Jorgensen Scott,  Biyyam Deepa,  Patel Mittun,  Cassell Ian

Final Pr. ID: Poster #: EDU-110

Accurate tumor measurement is essential in initial assessment of solid tumors. Furthermore, it is vital when evaluating treatment response. Change in tumor size determines whether a treatment course is effective, if treatment should be prolonged, or whether a more aggressive treatment or chemotherapy drug should be administered. Currently endorsed and widely used guidelines for tumor volume measurement include response evaluation criteria in solid tumors (RECIST), a one dimensional measure (cm) of target lesions which is not routinely the longest axis; World Health Organization (WHO), a 2 dimensional measure of the long and one short tumor axis (cm2) but is not a measure of volume; and Childrens Oncology Group (COG), a 3 dimensional ‘volume’ (cm3) measurement but does not account for shape of the tumor.

Pediatric oncology patients are almost exclusively cared for in major academic or community hospital settings where modern CT and MR scanners routinely produce direct or reconstructed multiplanar images. Therefore an evolution of tumor measurement, to determine tumor volume, must be forthcoming. Read More

Authors:  Willard Scott , Barnes Craig , Augustyn Robyn , Thorkelson Marrit , Chatfield Paige , Hu Harry , Towbin Richard , Bardo Dianna , Pfeifer Cory , Dance Logan , Bailey Smita , Southard Richard , Jorgensen Scott , Biyyam Deepa , Patel Mittun , Cassell Ian

Keywords:  RECIST, WHO, COG